Download NC-PB-22 8-Hydroxyisoquinoline isomer-2013-08

Health Canada
Santé Canada
STATUS DECISION OF CONTROLLED
AND NON-CONTROLLED SUBSTANCE(S)
Substance: PB-22 8-Hydroxyisoquinoline isomer
Based on the current information available to the Office of Controlled Substances, it appears that
the above substance is:
Controlled
Not Controlled
☐
X
under the schedules of the Controlled Drugs and Substances Act (CDSA) for the following
reason(s):

The efficacy of PB-22 8-Hydroxyisoquinoline isomer as a cannabinoid receptor agonist
has not been established and therefore the substance cannot be included under item 1 of
Schedule II to the CDSA.
Prepared by: _______________________________________
Vincent Marleau
Date: _______________
Verified by:
Date: ________________
_______________________________________
Mark Kozlowski
Approved by: _______________________________________
Date: ________________
DIRECTOR, OFFICE OF CONTROLLED SUBSTANCES
This status was requested by: “third party information removed as per agreement with applicant”
2
Drug Status Report
Drug: PB-22 8-Hydroxyisoquinoline isomer
Drug Name Status: PB-22 8-Hydroxyisoquinoline isomer is the common name.
Chemical Name: Isoquinolin-8-yl 1-pentyl-1H-indole-3-carboxylate
Chemical structure:
Molecular Formula: C23H22N2O2
CAS-RN: N/A
Pharmacological class / Application: Synthetic cannabinoid
International status:
US: PB-22 8-Hydroxyisoquinoline isomer is not listed specifically in the Schedules to the US
Controlled Substances Act and is not mentioned anywhere on the DEA website.
United Nations: The substance is not listed on the Yellow List - List of Narcotic Drugs under
International Control, the Green List - List of Psychotropic Substances under International
Control, nor the Red List - List of Precursors and Chemicals Frequently Used in the Illicit
Manufacture of Narcotic Drugs and Psychotropic Substances under International Control.
Canadian Status: PB-22 8-Hydroxyisoquinoline isomer is not listed in the Schedules to the
CDSA. The substance is a synthetic cannabinoid but there are currently no reports in the
scientific literature on the efficacy of the substance as a cannabinoid receptor agonist.
Cannabinoid receptor agonists are captured under item 1 of Schedule II to the CDSA by virtue of
being “similar synthetic preparations” while cannabinoid receptor antagonists are not included
under Schedule II to the CDSA. Since it cannot be established whether this substance is an
efficient cannabinoid receptor agonist, PB-22 8-Hydroxyisoquinoline isomer cannot be included
under item 1 of Schedule II to the CDSA.
Recommendation: PB-22 8-Hydroxyisoquinoline isomer is not included in the schedules to the
CDSA and is not a controlled substance.
Date: August 1st, 2013.